Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 05, 2021 07:30 ET
|
Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
December 21, 2020 07:00 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...
Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic
November 30, 2020 09:00 ET
|
Innovation Pharmaceuticals Inc.
Company advancing Brilacidin as a next-generation broad-spectrum antiviral for the treatment of common colds and deadly coronavirus infections WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) --...
Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line
July 20, 2020 07:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing...
Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020
July 13, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned...
In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial
July 07, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports the latest developments related...
Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
June 17, 2020 07:30 ET
|
Innovation Pharmaceuticals Inc.
Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...
Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic
June 11, 2020 07:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
May 26, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19
April 06, 2020 07:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in...